Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Enhancement of Antitumor Vaccination by Targeting Dendritic Cell-Related IL-10.

Llopiz D, Ruiz M, Silva L, Sarobe P.

Front Immunol. 2018 Sep 3;9:1923. doi: 10.3389/fimmu.2018.01923. eCollection 2018. Review.

2.

The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer.

Villanueva L, Silva L, Llopiz D, Ruiz M, Iglesias T, Lozano T, Casares N, Hervas-Stubbs S, Rodríguez MJ, Carrascosa JL, Lasarte JJ, Sarobe P.

Oncoimmunology. 2017 Dec 21;7(4):e1409321. doi: 10.1080/2162402X.2017.1409321. eCollection 2018.

PMID:
29632721
3.

Immunomodulatory Properties of Carvone Inhalation and Its Effects on Contextual Fear Memory in Mice.

Lasarte-Cia A, Lozano T, Pérez-González M, Gorraiz M, Iribarren K, Hervás-Stubbs S, Sarobe P, Rabal O, Cuadrado-Tejedor M, García-Osta A, Casares N, Lasarte JJ.

Front Immunol. 2018 Jan 25;9:68. doi: 10.3389/fimmu.2018.00068. eCollection 2018.

4.

Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor.

Lozano T, Gorraiz M, Lasarte-Cía A, Ruiz M, Rabal O, Oyarzabal J, Hervás-Stubbs S, Llopiz D, Sarobe P, Prieto J, Casares N, Lasarte JJ.

Oncotarget. 2017 May 13;8(42):71709-71724. doi: 10.18632/oncotarget.17845. eCollection 2017 Sep 22.

5.

PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity.

Gato-Cañas M, Zuazo M, Arasanz H, Ibañez-Vea M, Lorenzo L, Fernandez-Hinojal G, Vera R, Smerdou C, Martisova E, Arozarena I, Wellbrock C, Llopiz D, Ruiz M, Sarobe P, Breckpot K, Kochan G, Escors D.

Cell Rep. 2017 Aug 22;20(8):1818-1829. doi: 10.1016/j.celrep.2017.07.075.

6.

Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy.

Fernandez-Poma SM, Salas-Benito D, Lozano T, Casares N, Riezu-Boj JI, Mancheño U, Elizalde E, Alignani D, Zubeldia N, Otano I, Conde E, Sarobe P, Lasarte JJ, Hervas-Stubbs S.

Cancer Res. 2017 Jul 1;77(13):3672-3684. doi: 10.1158/0008-5472.CAN-17-0236. Epub 2017 May 18.

7.

IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination.

Llopiz D, Ruiz M, Infante S, Villanueva L, Silva L, Hervas-Stubbs S, Alignani D, Guruceaga E, Lasarte JJ, Sarobe P.

Oncotarget. 2017 Jan 10;8(2):2659-2671. doi: 10.18632/oncotarget.13736.

8.

Vaccine-induced but not tumor-derived Interleukin-10 dictates the efficacy of Interleukin-10 blockade in therapeutic vaccination.

Llopiz D, Aranda F, Díaz-Valdés N, Ruiz M, Infante S, Belsúe V, Lasarte JJ, Sarobe P.

Oncoimmunology. 2015 Aug 12;5(2):e1075113. eCollection 2016 Feb.

9.

Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance.

Zabaleta A, Riezu-Boj JI, Larrea E, Villanueva L, Lasarte JJ, Guruceaga E, Fisicaro P, Ezzikouri S, Missale G, Ferrari C, Benjelloun S, Prieto J, Sarobe P.

J Med Virol. 2016 May;88(5):843-51. doi: 10.1002/jmv.24399. Epub 2015 Oct 19.

PMID:
26447929
10.

Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation.

Lozano T, Villanueva L, Durántez M, Gorraiz M, Ruiz M, Belsúe V, Riezu-Boj JI, Hervás-Stubbs S, Oyarzábal J, Bandukwala H, Lourenço AR, Coffer PJ, Sarobe P, Prieto J, Casares N, Lasarte JJ.

J Immunol. 2015 Oct 1;195(7):3180-9. doi: 10.4049/jimmunol.1402997. Epub 2015 Aug 31.

11.

Immune monitoring of immunosuppression withdrawal of liver transplant recipients.

García de la Garza R, Sarobe P, Merino J, Lasarte JJ, D'Avola D, Belsue V, Delgado JA, Silva L, Iñarrairaegui M, Sangro B, Sola I, Pardo F, Quiroga J, Ignacio Herrero J.

Transpl Immunol. 2015 Oct;33(2):110-6. doi: 10.1016/j.trim.2015.07.006. Epub 2015 Jul 29.

PMID:
26225458
12.

Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection.

Zabaleta A, D'Avola D, Echeverria I, Llopiz D, Silva L, Villanueva L, Riezu-Boj JI, Larrea E, Pereboev A, Lasarte JJ, Rodriguez-Lago I, Iñarrairaegui M, Sangro B, Prieto J, Sarobe P.

Mol Ther Methods Clin Dev. 2015 Mar 11;2:15006. doi: 10.1038/mtm.2015.6. eCollection 2015.

13.

Tim-3 expression in tumour-associated macrophages: a new player in HCC progression.

Flecken T, Sarobe P.

Gut. 2015 Oct;64(10):1502-3. doi: 10.1136/gutjnl-2014-309094. Epub 2015 Feb 18. No abstract available.

PMID:
25694141
14.

Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation.

Fernandez-Ros N, Iñarrairaegui M, Paramo JA, Berasain C, Avila MA, Chopitea A, Varo N, Sarobe P, Bilbao JI, Dominguez I, D'Avola D, Herrero JI, Quiroga J, Sangro B.

Liver Int. 2015 May;35(5):1590-6. doi: 10.1111/liv.12592. Epub 2014 Jun 3.

PMID:
24836705
15.

Helper cell-independent antitumor activity of potent CD8+ T cell epitope peptide vaccines is dependent upon CD40L.

Llopiz D, Huarte E, Ruiz M, Bezunartea J, Belsúe V, Zabaleta A, Lasarte JJ, Prieto J, Borrás-Cuesta F, Sarobe P.

Oncoimmunology. 2013 Dec 1;2(12):e27009. Epub 2013 Dec 5.

16.

Characterization of the CD40L/Oncostatin M/Oncostatin M receptor axis as an antiviral and immunostimulatory system disrupted in chronic HCV infection.

Larrea E, Echeverria I, Riezu-Boj JI, Aldabe R, Guembe L, Sola I, Civeira MP, Sarobe P, Prieto J.

J Hepatol. 2014 Mar;60(3):482-9. doi: 10.1016/j.jhep.2013.10.016. Epub 2013 Oct 26.

PMID:
24418171
17.

A fusion protein between streptavidin and the endogenous TLR4 ligand EDA targets biotinylated antigens to dendritic cells and induces T cell responses in vivo.

Arribillaga L, Durantez M, Lozano T, Rudilla F, Rehberger F, Casares N, Villanueva L, Martinez M, Gorraiz M, Borrás-Cuesta F, Sarobe P, Prieto J, Lasarte JJ.

Biomed Res Int. 2013;2013:864720. doi: 10.1155/2013/864720. Epub 2013 Sep 5.

18.

Dysregulation of interferon regulatory factors impairs the expression of immunostimulatory molecules in hepatitis C virus genotype 1-infected hepatocytes.

Larrea E, Riezu-Boj JI, Aldabe R, Guembe L, Echeverria I, Balasiddaiah A, Gastaminza P, Civeira MP, Sarobe P, Prieto J.

Gut. 2014 Apr;63(4):665-73. doi: 10.1136/gutjnl-2012-304377. Epub 2013 Jun 20.

PMID:
23787026
19.

Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance.

de la Garza RG, Sarobe P, Merino J, Lasarte JJ, D'Avola D, Belsue V, Delgado JA, Silva L, Iñarrairaegui M, Sangro B, Sola JJ, Pardo F, Quiroga J, Herrero JI.

Liver Transpl. 2013 Sep;19(9):937-44. doi: 10.1002/lt.23686. Epub 2013 Jul 26.

20.

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera P, Riezu-Boj JI, Larrea E, Alfaro C, Sarobe P, Lasarte JJ, Pérez-Gracia JL, Melero I, Prieto J.

J Hepatol. 2013 Jul;59(1):81-8. doi: 10.1016/j.jhep.2013.02.022. Epub 2013 Mar 4.

PMID:
23466307
21.

Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses.

Rudilla F, Fayolle C, Casares N, Durantez M, Arribillaga L, Lozano T, Villanueva L, Pio R, Sarobe P, Leclerc C, Prieto J, Lasarte JJ.

Vaccine. 2012 Apr 16;30(18):2848-58. doi: 10.1016/j.vaccine.2012.02.052. Epub 2012 Mar 2.

22.

Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin.

Mansilla C, Berraondo P, Durantez M, Martínez M, Casares N, Arribillaga L, Rudilla F, Fioravanti J, Lozano T, Villanueva L, Sarobe P, Borrás F, Leclerc C, Prieto J, Lasarte JJ.

Int J Cancer. 2012 Aug 1;131(3):641-51. doi: 10.1002/ijc.26412. Epub 2011 Oct 5.

23.

Low molecular weight hyaluronan preconditioning of tumor-pulsed dendritic cells increases their migratory ability and induces immunity against murine colorectal carcinoma.

Alaniz L, Rizzo M, Garcia MG, Piccioni F, Aquino JB, Malvicini M, Atorrasagasti C, Bayo J, Echeverria I, Sarobe P, Mazzolini G.

Cancer Immunol Immunother. 2011 Oct;60(10):1383-95. doi: 10.1007/s00262-011-1036-0. Epub 2011 Jun 3.

PMID:
21638126
24.

Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells.

Echeverria I, Pereboev A, Silva L, Zabaleta A, Riezu-Boj JI, Bes M, Cubero M, Borras-Cuesta F, Lasarte JJ, Esteban JI, Prieto J, Sarobe P.

Hepatology. 2011 Jul;54(1):28-37. doi: 10.1002/hep.24325. Epub 2011 May 14.

25.

Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors.

Aranda F, Llopiz D, Díaz-Valdés N, Riezu-Boj JI, Bezunartea J, Ruiz M, Martínez M, Durantez M, Mansilla C, Prieto J, Lasarte JJ, Borrás-Cuesta F, Sarobe P.

Cancer Res. 2011 May 1;71(9):3214-24. doi: 10.1158/0008-5472.CAN-10-3259. Epub 2011 Mar 14.

26.

International symposium on CTL and immunostimulation, Pamplona (Spain), October 26th and 27th 2010.

Ochoa MC, Hervas-Stubbs S, Palazon A, Martinez-Forero I, Berraondo P, Sarobe P, Melcher A, Melero I.

Cancer Immunol Immunother. 2011 May;60(5):753-6. doi: 10.1007/s00262-011-1000-z. Epub 2011 Mar 5. No abstract available.

PMID:
21380561
27.

Therapeutic effect of a peptide inhibitor of TGF-β on pulmonary fibrosis.

Arribillaga L, Dotor J, Basagoiti M, Riezu-Boj JI, Borrás-Cuesta F, Lasarte JJ, Sarobe P, Cornet ME, Feijoó E.

Cytokine. 2011 Mar;53(3):327-33. doi: 10.1016/j.cyto.2010.11.019. Epub 2010 Dec 23.

PMID:
21185199
28.

Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFbeta1 in melanoma enhances tumor infiltration and immunosuppression.

Díaz-Valdés N, Basagoiti M, Dotor J, Aranda F, Monreal I, Riezu-Boj JI, Borrás-Cuesta F, Sarobe P, Feijoó E.

Cancer Res. 2011 Feb 1;71(3):812-21. doi: 10.1158/0008-5472.CAN-10-2698. Epub 2010 Dec 15.

29.

Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10.

Díaz-Valdés N, Manterola L, Belsúe V, Riezu-Boj JI, Larrea E, Echeverria I, Llópiz D, López-Sagaseta J, Lerat H, Pawlotsky JM, Prieto J, Lasarte JJ, Borrás-Cuesta F, Sarobe P.

Hepatology. 2011 Jan;53(1):23-31. doi: 10.1002/hep.23980. Epub 2010 Dec 13.

30.

Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection.

Riezu-Boj JI, Larrea E, Aldabe R, Guembe L, Casares N, Galeano E, Echeverria I, Sarobe P, Herrero I, Sangro B, Prieto J, Lasarte JJ.

J Hepatol. 2011 Mar;54(3):422-31. doi: 10.1016/j.jhep.2010.07.014. Epub 2010 Sep 26.

31.

A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice.

Casares N, Rudilla F, Arribillaga L, Llopiz D, Riezu-Boj JI, Lozano T, López-Sagaseta J, Guembe L, Sarobe P, Prieto J, Borrás-Cuesta F, Lasarte JJ.

J Immunol. 2010 Nov 1;185(9):5150-9. doi: 10.4049/jimmunol.1001114. Epub 2010 Sep 24.

32.

Tumor therapy in mice by using a tumor antigen linked to modulin peptides from Staphylococcus epidermidis.

Durantez M, Fayolle C, Casares N, Belsue V, Riezu-Boj JI, Sarobe P, Prieto J, Borrás-Cuesta F, Leclerc C, Lasarte JJ.

Vaccine. 2010 Oct 18;28(44):7146-54. doi: 10.1016/j.vaccine.2010.08.070. Epub 2010 Sep 15.

33.

Identification of CD4+ and CD8+ T cell epitopes of woodchuck hepatitis virus core and surface antigens in BALB/c mice.

Ochoa-Callejero L, Otano I, Vales A, Olagüe C, Sarobe P, Lasarte JJ, Prieto J, Menne S, González-Aseguinolaza G.

Vaccine. 2010 Jul 19;28(32):5323-31.

PMID:
20665977
34.

The epidermal growth factor receptor ligand amphiregulin is a negative regulator of hepatic acute-phase gene expression.

Pardo-Saganta A, Latasa MU, Castillo J, Alvarez-Asiain L, Perugorría MJ, Sarobe P, Rodriguez-Ortigosa CM, Prieto J, Berasain C, Santamaría M, Avila MA.

J Hepatol. 2009 Dec;51(6):1010-20. doi: 10.1016/j.jhep.2009.06.030. Epub 2009 Sep 12.

35.

Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein.

Mansilla C, Gorraiz M, Martinez M, Casares N, Arribillaga L, Rudilla F, Echeverria I, Riezu-Boj JI, Sarobe P, Borrás-Cuesta F, Prieto J, Lasarte JJ.

J Hepatol. 2009 Sep;51(3):520-7. doi: 10.1016/j.jhep.2009.06.005. Epub 2009 Jun 23.

36.

Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy.

Llopiz D, Dotor J, Casares N, Bezunartea J, Díaz-Valdés N, Ruiz M, Aranda F, Berraondo P, Prieto J, Lasarte JJ, Borrás-Cuesta F, Sarobe P.

Int J Cancer. 2009 Dec 1;125(11):2614-23. doi: 10.1002/ijc.24656.

37.

Oncostatin M enhances the antiviral effects of type I interferon and activates immunostimulatory functions in liver epithelial cells.

Larrea E, Aldabe R, Gonzalez I, Segura V, Sarobe P, Echeverria I, Prieto J.

J Virol. 2009 Apr;83(7):3298-311. doi: 10.1128/JVI.02167-08. Epub 2009 Jan 21.

38.

Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.

Durántez M, López-Vázquez AB, de Cerio AL, Huarte E, Casares N, Prieto J, Borrás-Cuesta F, Lasarte JJ, Sarobe P.

Scand J Immunol. 2009 Feb;69(2):80-9. doi: 10.1111/j.1365-3083.2008.02202.x. Epub 2008 Dec 10.

39.

A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats.

Hermida N, López B, González A, Dotor J, Lasarte JJ, Sarobe P, Borrás-Cuesta F, Díez J.

Cardiovasc Res. 2009 Feb 15;81(3):601-9. doi: 10.1093/cvr/cvn315. Epub 2008 Nov 19.

40.

Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity.

Huarte E, Cubillos-Ruiz JR, Nesbeth YC, Scarlett UK, Martinez DG, Buckanovich RJ, Benencia F, Stan RV, Keler T, Sarobe P, Sentman CL, Conejo-Garcia JR.

Cancer Res. 2008 Sep 15;68(18):7684-91. doi: 10.1158/0008-5472.CAN-08-1167. Epub 2008 Sep 3.

41.

Monocyte-derived dendritic cells from HCV-infected patients transduced with an adenovirus expressing NS3 are functional when stimulated with the TLR3 ligand poly(I:C).

Echeverría I, Zabaleta A, Silva L, Díaz-Valdés N, Riezu-Boj JI, Lasarte JJ, Borrás-Cuesta F, Civeira MP, Prieto J, Sarobe P.

J Viral Hepat. 2008 Nov;15(11):782-9. doi: 10.1111/j.1365-2893.2008.01020.x. Epub 2008 Jul 10.

PMID:
18637068
42.

In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-beta1.

Gil-Guerrero L, Dotor J, Huibregtse IL, Casares N, López-Vázquez AB, Rudilla F, Riezu-Boj JI, López-Sagaseta J, Hermida J, Van Deventer S, Bezunartea J, Llopiz D, Sarobe P, Prieto J, Borrás-Cuesta F, Lasarte JJ.

J Immunol. 2008 Jul 1;181(1):126-35.

43.

Cells as vehicles for therapeutic genes to treat liver diseases.

Prieto J, Fernandez-Ruiz V, Kawa MP, Sarobe P, Qian C.

Gene Ther. 2008 May;15(10):765-71. doi: 10.1038/gt.2008.44. Epub 2008 Apr 3. Review.

44.

Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein.

Zabaleta A, Llopiz D, Arribillaga L, Silva L, Riezu-Boj JI, Lasarte JJ, Borrás-Cuesta F, Prieto J, Sarobe P.

Mol Ther. 2008 Jan;16(1):210-7. Epub 2007 Oct 9.

45.

Identification of peptide inhibitors of transforming growth factor beta 1 using a phage-displayed peptide library.

Dotor J, López-Vázquez AB, Lasarte JJ, Sarobe P, García-Granero M, Riezu-Boj JI, Martínez A, Feijoó E, López-Sagaseta J, Hermida J, Prieto J, Borrás-Cuesta F.

Cytokine. 2007 Aug;39(2):106-15. Epub 2007 Sep 4.

46.

Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects.

Llopiz D, Dotor J, Zabaleta A, Lasarte JJ, Prieto J, Borrás-Cuesta F, Sarobe P.

Cancer Immunol Immunother. 2008 Jan;57(1):19-29. Epub 2007 Jun 13.

47.

The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFN gamma.

Arina A, Murillo O, Hervás-Stubbs S, Azpilikueta A, Dubrot J, Tirapu I, Huarte E, Alfaro C, Pérez-Gracia JL, González-Aseguinolaza G, Sarobe P, Lasarte JJ, Jamieson A, Prieto J, Raulet DH, Melero I.

Int J Cancer. 2007 Sep 15;121(6):1282-95.

48.

Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40.

Zabaleta A, Arribillaga L, Llopiz D, Dotor J, Lasarte JJ, Prieto J, Borrás-Cuesta F, Esteban JI, Quer J, Vayreda F, Sarobe P.

Antiviral Res. 2007 Apr;74(1):25-35. Epub 2007 Jan 22.

49.

Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection.

Larrea E, Riezu-Boj JI, Gil-Guerrero L, Casares N, Aldabe R, Sarobe P, Civeira MP, Heeney JL, Rollier C, Verstrepen B, Wakita T, Borrás-Cuesta F, Lasarte JJ, Prieto J.

J Virol. 2007 Apr;81(7):3662-6. Epub 2007 Jan 17.

50.

The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo.

Lasarte JJ, Casares N, Gorraiz M, Hervás-Stubbs S, Arribillaga L, Mansilla C, Durantez M, Llopiz D, Sarobe P, Borrás-Cuesta F, Prieto J, Leclerc C.

J Immunol. 2007 Jan 15;178(2):748-56.

Supplemental Content

Loading ...
Support Center